Q-omics provides the consensus-scored RIPOR1 profile across patient tissues and cancer cell-line models. RIPOR1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RIPOR1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RIPOR1 protein abundance shows 25,134 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, HNSC, and LSCC as cancer lineages where RIPOR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIPOR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIPOR1 survival associations across molecular data types. RIPOR1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIPOR1 RNA expression–survival associations across cancer types. High RIPOR1 expression shows unfavorable associations in LUSC, COAD, HNSC, ACC and BLCA, but favorable associations in KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RIPOR1 RNA expression.
This table summarizes RIPOR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RIPOR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIPOR1 shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in HNSC, LIHC and COAD. The HNSC box plot shows higher RIPOR1 RNA expression in tumor versus normal tissue (log2 FC = +0.762, t-test p < 0.001).
This table shows molecular features associated with RIPOR1 in patient tissues and cancer cell lines. In patient samples, RIPOR1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RIPOR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUSC.
